Cmic
Cmic is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis
Sponsor Trace Neuroscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, open label, multicenter, Phase 2 study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® in combination with mFOLFOX6 and bevacizumab versus standard of care for first-line treatment of non-MSI-H/dMMR, PD-L1 positive advanced colorectal cancer.
Sponsor Ono Pharmaceutical Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
MT-7117-A-302 Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria
Sponsor Tanabe Pharma America Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE II, RANDOMIZED, DOUBLE BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMY109 IN WOMEN WITH ENDOMETRIOSIS
Sponsor Chugai Pharmaceutical Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects with Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Tumors are Claudin (CLDN) 18.2 Positive.
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Cmic?
The 2026-10-09 snapshot links Cmic to 12 distinct CTIS trials. Recorded services include Laboratory services, Electronic data capture, Plasma samples for soticlestat and metabolite(s) PK and 24HC. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cmic?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Allergy, Dermatology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cmic conducted?
The linked trials record locations in 16 countries, including Spain, Italy, France, Poland, Germany. These are trial locations, not confirmed office locations or countries where Cmic delivered services.
What can this page tell me about Cmic's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Cmic. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cmic Inc.